Simon Ekman
YOU?
Author Swipe
View article: SURFR: genome-free discovery of cancer-unique small RNAs from cohort sequencing data
SURFR: genome-free discovery of cancer-unique small RNAs from cohort sequencing data Open
Small RNAs play numerous roles in cancer biology and function as biomarkers and therapeutic targets. A recently discovered class of small RNAs - the orphan non-coding RNAs (oncRNAs) - are uniquely present in cancer and absent from healthy …
View article: The stereotactic radiosurgery-brain prognostic index (SRS-BPI): A novel prognostic index for SRS-eligible lung cancer patients with brain metastases
The stereotactic radiosurgery-brain prognostic index (SRS-BPI): A novel prognostic index for SRS-eligible lung cancer patients with brain metastases Open
The SRS-BPI emerges as an internally validated, advanced prognostic tool, providing enhanced decision-making support for lung cancer patients with BM who are candidates for SRS. Although internally validated, external validation is essenti…
View article: Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer—a retrospective cohort study
Predictors of survival and recurrence patterns following definitive chemoradiotherapy in stage III non-small cell lung cancer—a retrospective cohort study Open
Routine diagnostic parameters can be used to predict survival and recurrence patterns in patients receiving curative CRT. Additionally, salvage treatment with immunotherapy was the strongest factor associated with longer survival after dis…
View article: Chaperone-mediated autophagy regulates the metastatic state of mesenchymal tumors
Chaperone-mediated autophagy regulates the metastatic state of mesenchymal tumors Open
Tumors often recapitulate programs to acquire invasive and dissemination abilities, during which pro-metastatic proteins are distinctively stabilized in cancer cells to drive further progression. Whether failed protein degradation affects …
View article: NTRK Gene Expression in Non-Small-Cell Lung Cancer
NTRK Gene Expression in Non-Small-Cell Lung Cancer Open
Background/Objectives: Since the discovery of oncogenic neurotrophic receptor tyrosine kinase (NTRK) gene fusions in colorectal cancer in 1986, their understanding has evolved, particularly in non-small-cell lung cancer (NSCLC) over the pa…
View article: A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers Open
In the largest real-word data study of KRAS-mutated NSCLC patients with BM, we developed a novel prognostic tool for improved patient stratification.
View article: Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study
Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study Open
This comprehensive study, spanning over a decade, provides crucial insights into the clinical characteristics, treatment patterns, and resistance mechanisms of advanced ALK-positive NSCLC, where median OS exceeds 5 years. Re-biopsies durin…
View article: PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer
PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer Open
Introduction Programmed death ligand – 1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed death – 1 (PD-1) serves as the target protein to PD-L1 and their int…
View article: The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain Metastases
The Brain-Lung Immunotherapy Prognostic (BLIP) Score: A Novel Robust Tool for Prognostication in Non-Small Cell Lung Cancer Patients with Brain Metastases Open
Background Lung cancer remains the leading cause of cancer-related mortality, with brain metastases (BMs) significantly worsening prognosis and quality of life. The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treat…
View article: Trends in lung cancer survival in the Nordic countries 1990–2016: The NORDCAN survival studies
Trends in lung cancer survival in the Nordic countries 1990–2016: The NORDCAN survival studies Open
Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from thei…
View article: Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors Open
The treatment landscape of solid tumors has changed markedly in the last years. Molecularly targeted treatments and immunotherapies have been implemented and have, in many cancers, lowered the risk of relapse and prolonged survival. Patien…
View article: Correction: Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers
Correction: Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers Open
[This corrects the article DOI: 10.1371/journal.pone.0276703.].
View article: Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors Open
[This corrects the article DOI: 10.1371/journal.pone.0277708.].
View article: Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals
Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals Open
Our data suggest limited survival benefits from METi, ICIs, and chemotherapy for METex14 lung cancer patients. While not statistically significant, these findings underscore the need for larger trials for validation. Identifying effective …
View article: Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer
Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer Open
Our approach of combining ctDNA and exosomal RNA analyses in CSF presents a potential surrogate for BM biopsy. The specific variants that were only observed in the CNS compartments could serve as targets for individually tailored therapies…
View article: Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis Open
The presence of brain metastases (BM) is a negative prognostic factor for patients with advanced nonsmall cell lung cancer (NSCLC). Their incidence seems to be higher in patients with oncogene‐driven tumours, especially those with EGFR ‐mu…
View article: Supplementary Table 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Table 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 29K, Characteristics of NSCLC patients from Uppsala for tissue microarray analysis
View article: Supplementary Discussion from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Discussion from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 117K, Analysis of the 14 gene sinature risk score of Kratz et al., 2012
View article: Supplementary Figure 2 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Figure 2 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 312K, Kaplan-Meier suvival plots of the Uppsala cohort for the top prognostic genes according to gene expression
View article: Supplementary Table 4 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Table 4 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
XLSX file - 24K, Excel file including uni- and multivariate analysis of the top 17 prognostic probe sets
View article: Supplementary Table 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Table 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 29K, Characteristics of NSCLC patients from Uppsala for tissue microarray analysis
View article: Supplementary Table 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Table 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
XLSX file - 155K, Excel file of probe sets that were associated with survival in the Uppsala cohort for all histological subtypes, adenocarcinoma and sqaumous cell cancer
View article: Supplementary Figure 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Figure 1 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 123K, Survival plot and Kaplan-Meier analysis of clinical parameters in the Uppsala cohort
View article: Supplementary Figure 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Supplementary Figure 3 from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
PDF file - 41K, Kaplan-Meier plots of recurrence free survival according CADM1 gene expression
View article: Data from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation
Data from Biomarker Discovery in Non–Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation Open
Purpose: Global gene expression profiling has been widely used in lung cancer research to identify clinically relevant molecular subtypes as well as to predict prognosis and therapy response. So far, the value of these multigene signatures…